VSE LI MY ZNAEM O VOZMOZhNOSTYaKh LEChENIYa STEROIDNOGO OSTEOPOROZA?


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Secondary osteoporosis is closely associated with a number of endocrine diseases. Steroid-induced osteoporosis is the most common form of secondary osteoporosis. The steroid-induced osteoporosis develops due to endogenous hypercortisolism, rather rare, but severe disease. Osteoporosis as one of the dangerous consequences of treatment with pharmacologic doses of glucocorticosteroids (exogenous hypercortisolism) is a more frequent problem. The article discusses the pathogenetic mechanisms of steroid-induced osteoporosis and the influence of an excess of glucocorticosteroids on bone remodeling processes. It is emphasized that the timely appointment of antiresorptive pharmacotherapy in patients with steroid-induced osteoporosis allows to delay or stop the loss of bone mass, and provides low incidence of bone fractures, and bisphosphonates are considered as a first-line therapy for steroid-induced osteoporosis.

Texto integral

Acesso é fechado

Sobre autores

E. Biryukova

Email: lena@obsudim.ru

Bibliografia

  1. Heaney RP. Advances in therapy for osteoporosis. Clin Med Res 2003;1(2):93-9.
  2. Cauley JA, Thompson DE et al. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61.
  3. Bouvard B, Audran M, Legrand E, Chappard D. Ultrastructural characteristics of glucocorticoid-induced osteoporosis. Osteoporos Int 2009;20:1089-92.
  4. Painter SE, Kleerekoper M, Camacho PM. Secondary osteoporosis: a review of the recent evidence. Endocr Pract 2006;12(4):436-45.
  5. Риггз Б.Л., Мелтон III Л.Д. Остеопороз. Этиология, диагностика, лечение. М., 2000. 558 с.
  6. Canalis E. Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 2003;15(4):454-57.
  7. Насонова Е.Л. Клинические рекомендации. Ревматология. М., 2010. 282 с.
  8. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Obes Res 1994;2:486-508.
  9. Van Staa T, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis.Osteopros Int 2002;13:777-87.
  10. Van Staa TP, Leufkens HGM, Abenhaim L, Begaud B et al. Use of oral corticosteroids in the United Kingdom. Q J Med 2000;93:105-11.
  11. Van Staa T, Leufkens H, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
  12. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007;18:1319-28.
  13. Коршунов Н.И., Ершова О.Б., Белова К.Ю. Глюкокортикоидный остеопороз: диагностика и лечение// РМЖ 2007;6:546-49.
  14. Roche WR, Beasley R, Williams JH. Subepithelial fibrosis in the bronchi of asthmatics text. Lancet 1989;139:520-23.
  15. Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-29.
  16. Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000;106:651-59.
  17. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
  18. Natsui K, Tanaka K, Suda M et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17:105-108.
  19. Peacock M. Calcium metabolism in health and disease. CJASN 2010;5:23-30.
  20. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 2000;343:1863-75.
  21. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001;2:65-73.
  22. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin.Invest 1998;102:274-82.
  23. Weinstein RS, Chen JR, Powers CC, et al. Promotion of osteoclasts survival and antagonism of bisphosphonate induced osteoclasts apoptosis by glucocorticoids. J Clin invest 2002;109:1041-48.
  24. O'Brien CA, Jia D, Plotkin L, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation. Endocrinology 2004;145:1835-41.
  25. Lane NE, An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27:131-36.
  26. Hofbauer LC, Rauner M. Live and let die: effects of glucocorticoids on bone cells. Molec Endocrinol 2009;23:1525-31.
  27. Van Rossum EF, Lamberts SW. Polymorphism in the glucocorticosteroid Receptor gene and their association with metabolic parameters and body composition. Recent Prog Horm Res 2004;59:333-57.
  28. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14(2):279-98.
  29. Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularity. Bone 2010;46:564-70.
  30. Angeli A, Guglielmi G, Dovio A. et al. High prevalence of asymptomatic vertebral fractures inpost-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study. Bone 2000;39:253-59.
  31. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006; 81:662-72.
  32. Дедов И.И., Мельниченко Г.А. Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ: Руководство для практикующих врачей., 2006. 1114 с.
  33. Древаль А.В., Марченкова Л.А., Полякова Е.Ю. и др. Состояние костной ткани и риск развития остеопороза у женщин в стадии полной ремиссии болезни Иценко-Кушинга на фоне физиологической менопаузы// Остеопороз и остеопатии, 2007. № 3: С. 8-12.
  34. Teitelbaum SL, Seton MP, Saag KG. Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis & Rheumatism 2011;63:325-28.
  35. Nancollas GH, Tang R, Gulde S, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006;38:617-27.
  36. Rogers MJ. New insights into molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003;9:2643-58.
  37. Saag KG, Emkey R, Schnitzer TJ. Alendronat for the prevention and treatment of glucorticoid-induced osteoporosis Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-99.
  38. Adachi JD, Saag KG, Delmas PD. et al. Two-year effects of alerndronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, doubl-blind, placebo-controled extension trial. Arthritis Rheum. 2001;44:202-11.
  39. Sambrook PN, Kotowicz M, Nash P. et al. Prevention and treatment of glucorticoid-induced osteoporosis: a comparisonof calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003;18:919-24.
  40. Recker R, Lips P, Felsenberg D et al. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. Cuop Med Res Opin 2006;22: 1745-55.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies